BR0113376A - Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculina - Google Patents
Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculinaInfo
- Publication number
- BR0113376A BR0113376A BR0113376-4A BR0113376A BR0113376A BR 0113376 A BR0113376 A BR 0113376A BR 0113376 A BR0113376 A BR 0113376A BR 0113376 A BR0113376 A BR 0113376A
- Authority
- BR
- Brazil
- Prior art keywords
- testosterone
- drug release
- release system
- testosterone ester
- male contraceptive
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title abstract 3
- 229960003604 testosterone Drugs 0.000 title abstract 3
- -1 testosterone ester Chemical class 0.000 title abstract 3
- 239000003098 androgen Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002583 male contraceptive agent Substances 0.000 title 1
- ORGPUALGNXTPAW-UHFFFAOYSA-N 2,6-dichloro-n-(1-cyanocycloheptyl)benzamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1(C#N)CCCCCC1 ORGPUALGNXTPAW-UHFFFAOYSA-N 0.000 abstract 4
- 229960003410 testosterone decanoate Drugs 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 150000003515 testosterones Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
"USO DE UM éSTER DE TESTOSTERONA, MéTODO DE TRATAMENTO DE DISTúRBIOS DE INSUFICIêNCIA DE ANDROGêNIO, E, SISTEMA DE LIBERAçãO DE DROGA PARA CONTRACEPçãO MASCULINA". é revelada uma formulação de decanoato de testosterona para uso no tratamento de humanos. Ao contrário das formulações conhecidas compreendendo decanoato de testosterona, verificou-se que quaisquer outros esteres de testosterona, normalmente presentes juntos com o decanoato de testosterona, podem ser omitidos e a formulação, assim, compreende decanoato de testosterona como o único éster de testosterona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00202939 | 2000-08-23 | ||
PCT/EP2001/009569 WO2002015938A2 (en) | 2000-08-23 | 2001-08-17 | Testosterone ester formulation for human use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113376A true BR0113376A (pt) | 2003-07-15 |
Family
ID=8171940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0113376-4A BR0113376A (pt) | 2000-08-23 | 2001-08-17 | Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculina |
Country Status (15)
Country | Link |
---|---|
US (1) | US20050101517A1 (pt) |
EP (1) | EP1313511B1 (pt) |
JP (1) | JP2004506698A (pt) |
CN (1) | CN1248738C (pt) |
AT (1) | ATE311201T1 (pt) |
AU (2) | AU9177501A (pt) |
BR (1) | BR0113376A (pt) |
CA (1) | CA2415349A1 (pt) |
CY (1) | CY1106064T1 (pt) |
DE (1) | DE60115464T2 (pt) |
DK (1) | DK1313511T3 (pt) |
ES (1) | ES2253423T3 (pt) |
IL (2) | IL153648A0 (pt) |
MX (1) | MXPA03001147A (pt) |
WO (1) | WO2002015938A2 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200404552A (en) * | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
JO2505B1 (en) | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
IL157535A0 (en) * | 2003-08-21 | 2004-03-28 | Topimed Ltd | Preparations for the prevention of skin atrophy |
US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
EP2452670A1 (en) * | 2004-10-01 | 2012-05-16 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
AU2006236564B2 (en) | 2005-04-15 | 2011-02-17 | Tolmar, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
PL2519230T3 (pl) | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
TW201521731A (zh) * | 2013-03-15 | 2015-06-16 | 利波辛股份有限公司 | 用於口服之脂平衡的長鏈睪固酮酯 |
EP2968137B1 (en) | 2013-03-15 | 2021-11-10 | Marius Pharmaceuticals LLC | Emulsion formulations |
US10245273B2 (en) | 2013-12-26 | 2019-04-02 | Clarus Therapeutics, Inc. | Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2018064556A1 (en) | 2016-09-29 | 2018-04-05 | Gesea Biosciences Inc. | Bioerodible implant for long-term drug delivery and associated methods of manufacture and use |
CA3078723A1 (en) | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB465331A (en) * | 1935-10-05 | 1937-05-05 | Chem Ind Basel | Manufacture of new esters of polynuclear cyclic oxyketones |
NL189235C (nl) * | 1974-02-28 | 1993-02-16 | Akzo Nv | Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking. |
US4098802A (en) * | 1975-02-18 | 1978-07-04 | Akzona Incorporated | Oral pharmaceutical preparation having androgenic activity |
US4147783A (en) * | 1974-02-28 | 1979-04-03 | Akzona Incorporated | Oral pharmaceutical preparation |
NL7506407A (nl) * | 1975-05-30 | 1976-12-02 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat. |
GB1567515A (en) * | 1976-05-28 | 1980-05-14 | Akzo Nv | Esters of testo-sterone and 5 -dihydro-testosterone |
ATE86484T1 (de) * | 1987-08-08 | 1993-03-15 | Akzo Nv | Kontrazeptives implantat. |
US6063395A (en) * | 1998-11-12 | 2000-05-16 | Leiras Oy | Drug delivery device especially for the delivery of progestins and estrogens |
US7025979B2 (en) * | 2000-02-15 | 2006-04-11 | Schering Ag | Male contraceptive formulation comprising norethisterone |
-
2001
- 2001-08-17 US US10/362,350 patent/US20050101517A1/en not_active Abandoned
- 2001-08-17 AU AU9177501A patent/AU9177501A/xx active Pending
- 2001-08-17 DK DK01971928T patent/DK1313511T3/da active
- 2001-08-17 IL IL15364801A patent/IL153648A0/xx active IP Right Grant
- 2001-08-17 BR BR0113376-4A patent/BR0113376A/pt not_active IP Right Cessation
- 2001-08-17 CA CA002415349A patent/CA2415349A1/en not_active Abandoned
- 2001-08-17 DE DE60115464T patent/DE60115464T2/de not_active Expired - Fee Related
- 2001-08-17 MX MXPA03001147A patent/MXPA03001147A/es active IP Right Grant
- 2001-08-17 JP JP2002520859A patent/JP2004506698A/ja active Pending
- 2001-08-17 CN CNB018130542A patent/CN1248738C/zh not_active Expired - Fee Related
- 2001-08-17 ES ES01971928T patent/ES2253423T3/es not_active Expired - Lifetime
- 2001-08-17 AT AT01971928T patent/ATE311201T1/de not_active IP Right Cessation
- 2001-08-17 EP EP01971928A patent/EP1313511B1/en not_active Expired - Lifetime
- 2001-08-17 AU AU2001291775A patent/AU2001291775B2/en not_active Ceased
- 2001-08-17 WO PCT/EP2001/009569 patent/WO2002015938A2/en active IP Right Grant
-
2002
- 2002-12-25 IL IL153648A patent/IL153648A/en not_active IP Right Cessation
-
2006
- 2006-01-27 CY CY20061100113T patent/CY1106064T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE311201T1 (de) | 2005-12-15 |
CA2415349A1 (en) | 2002-02-28 |
EP1313511B1 (en) | 2005-11-30 |
US20050101517A1 (en) | 2005-05-12 |
AU9177501A (en) | 2002-03-04 |
DE60115464T2 (de) | 2006-06-14 |
DK1313511T3 (da) | 2006-03-20 |
AU2001291775B2 (en) | 2005-09-08 |
WO2002015938A3 (en) | 2002-08-15 |
DE60115464D1 (de) | 2006-01-05 |
WO2002015938A2 (en) | 2002-02-28 |
JP2004506698A (ja) | 2004-03-04 |
CN1248738C (zh) | 2006-04-05 |
IL153648A (en) | 2009-02-11 |
MXPA03001147A (es) | 2003-10-06 |
EP1313511A2 (en) | 2003-05-28 |
IL153648A0 (en) | 2003-07-06 |
CN1443078A (zh) | 2003-09-17 |
CY1106064T1 (el) | 2011-06-08 |
ES2253423T3 (es) | 2006-06-01 |
WO2002015938A8 (en) | 2004-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113376A (pt) | Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculina | |
IS2354B (is) | Lyfjasamsetning sem mögulegt er að hleypa | |
Grecomoro et al. | Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo | |
BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
GT199900151A (es) | Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial. | |
AU7998682A (en) | Continuous release pharmaceutical compositions | |
CY1106107T1 (el) | Φαρμακολογικες μορφοποιησεις που πepιλαμβανουν ρεσβepατρολη και χρηση αυτων | |
BR0014928A (pt) | Dispositivo e processo para distribuição de medicamento para um olho humano | |
DE60105448D1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
PE20040068A1 (es) | Decanoato, undecanoato y dodecanoato de etonogestrel | |
AR015933A1 (es) | Esmalte para unas con actividad antipsoriasica y procedimiento para su preparacion | |
PT881891E (pt) | Implante contaceptivo masculino | |
CA2216887A1 (en) | Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases | |
ES2166988T3 (es) | Terapia de administracion uniforme de farmacos. | |
AR026655A1 (es) | Nuevos esteroides con actividad androgenica y su uso como antinconceptivos masculinos y para tratar la insuficiencia androgenica | |
AR001765A1 (es) | Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales | |
CO4960657A1 (es) | Composicion farmaceutica | |
DK0753300T3 (da) | Anvendelse af steroider med antioxidative egenskaber til fremstilling af farmaceutiske præparater til medikamentøs substitu | |
AR003001A1 (es) | Composicion farmaceutica estimuladora de la osteogenesis. | |
BR9814136A (pt) | Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto. | |
AR011707A1 (es) | Composicion farmaceutica que comprende tirosina y un alergeno opcionalmente modificado, procedimiento para su preparacion y el uso de la misma para la manufactura de un medicamento. | |
BR0311248A (pt) | Kit de contracepção e/ou de hrt, usos de um éster de etonogestrel de ação prolongada, de um éster de etonogestrel de ação prolongada em conjunto com um éster de andrógeno de ação prolongada e de um éster de etonogestrel de ação prolongada em conjunto com um estrogênio, e, métodos de contracepção e /ou de hrt e de tratamento e/ou de prevenção de um distúrbio ginecológico feminino | |
GR3034803T3 (en) | Low-dose steroid tablets containing gallic acid esters as antioxidant agent, process for the manufacture of said tablets, and uses of said tablets | |
DE59911381D1 (de) | Verwendung von testosteronestern und/oder testosteron zur herstellung von bukkal applizierbaren bioadhasiven systemen mit zeitgesteuerter arzneistoffwirkung | |
ES2172172T3 (es) | Composiciones farmaceuticas solidas para la administracion por via oral que permiten la liberacion modulada de nicorandil y su procedimiento de preparacion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 9A. ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2077 DE 26/10/2010. |